ATHA | ATHIRA PHARMA INC

CUSIP: 04746L104

0 Funds Holding
0 Total Shares
$0 Total Value
$6.75
Price
$27M
Market Cap
P/E Ratio
-4.1
Forward P/E
$-9.67
EPS (TTM)
Dividend Yield
$25M
Cash
$1M
Total Debt
4M
Shares Out
$2.20
$8.36
52-Week Range

Institutional Ownership of ATHIRA PHARMA INC

Fund / Manager Click to search
Shares Value % of Portfolio Cost Basis Est. Return
No funds currently hold this stock.

Trading Activity for ATHIRA PHARMA INC

Fund / Manager Click to search
Action Change Shares After Value Price
2021-Q2
SELL EXIT $184.90
2020-Q3
BUY NEW 2.1M $39M $164.60

Insider Trading for ATHIRA PHARMA INC

6 Months Insider Sentiment
100%
Buy $0 Sell $43K
0 Buys
5 Sells
-43K Net
4 Grants
Largest
$6.3M LLC
$2.1M LLC
$18K Litton
Date
Insider Click to search
Role Click to search
Type Shares Price Value
Jan 02, 2026 Kevin Church CHIEF SCIENTIFIC OFFICER SELL 876 $6.88 $6K
Jan 02, 2026 Mark Worthington General Counsel and CCO SELL 876 $6.88 $6K
Jan 02, 2026 Robert Renninger Chief Financial Officer SELL 297 $6.88 $2K
Jan 02, 2026 Martin Javier San CHIEF MEDICAL OFFICER SELL 1.6K $6.88 $11K
Jan 02, 2026 Mark James Litton President and CEO SELL 2.6K $6.88 $18K
Dec 31, 2025 Martin Javier San CHIEF MEDICAL OFFICER EXERCISE 4.7K
Dec 31, 2025 Kevin Church CHIEF SCIENTIFIC OFFICER EXERCISE 3.7K
Dec 31, 2025 Mark James Litton President and CEO EXERCISE 10.8K
Dec 31, 2025 Mark Worthington General Counsel and CCO EXERCISE 3.7K
Dec 31, 2025 Robert Renninger Chief Financial Officer EXERCISE 1.2K
Dec 23, 2025 PERCEPTIVE ADVISORS LLC Director, 10% Owner GRANT 989.3K $6.35 $6.3M
Dec 23, 2025 PERCEPTIVE ADVISORS LLC Director, 10% Owner GRANT 329.8K $6.35 $2.1M
Nov 18, 2025 Robert Renninger Chief Financial Officer GRANT 1.0K $2.31 $2K
Nov 18, 2025 Kevin Church CHIEF SCIENTIFIC OFFICER GRANT 1.0K $2.31 $2K